Pharmaceutical products

Tender description

Invitation to offer for NHS National Framework Agreement for the Supply of Generic Pharmaceuticals – Interim 1 2020 Offer reference number: CM/PHG/20/5589 Period of framework agreement: The total maximum duration of the framework agreement to be no more than 24 months (12 months plus options to extend (at the Authority's sole discretion) for up to a further 12 months) Potential periods of call-offs under the framework agreement Hospital Only Products: DLS/DNE/DNW 1 August 2020 to 31 July 2021 (12 months) DLN/DCE/DSW 1 August 2020 to 31 July 2021 (12 months) Products on the framework include (but are not limited to): Darunavir Disodium Pamidronate Doxorubicin Epirubicin Ethambutol Etoposide Glycopyrronium Bromide Ibuprofen Irinotecan Lopinavir/Ritonavir Milrinone Posaconazole Ritonavir Salbutamol Tramadol Vancomycin. Details of presentation sizes and volumes are within the tender document set Invitation to offer for NHS National Framework Agreement for the Supply of Generic Pharmaceuticals – Interim 1 2020 Offer reference number: CM/PHG/20/5589 Period of framework agreement: The total maximum duration of the framework agreement to be no more than 24 months (12 months plus options to extend (at the Authority's sole discretion) for up to a further 12 months) Potential periods of call-offs under the framework agreement: 1 August 2020 to 31 July 2021 NHS National Framework Agreement for the Supply of Generic Pharmaceuticals – Interim 1 2020 Offer reference number: CM/PHG/20/5589 Period of framework agreement: the total maximum duration of the framework agreement to be no more than 24 months (12 months plus options to extend (at the Authority's sole discretion) for up to a further 12 months) Potential periods of call-offs under the framework agreement 1 August 2020 to 31 July 2021.